We have the highest-quality protein production and bioanalytic technology platform approach that allows us to create biosimilars in a highly efficient manner from concept to commercialization.
We are one of the only companies focused on non-glycosylated biosimilars, creating a differentiated platform approach and competitive advantage. This focus allows us to ensure a robust pipeline of high-quality therapeutics.
In addition, our unique protein production platform is well suited to vaccine development. By capitalizing on our ability to rapidly identify production strains for proteins that cannot be readily produced in other systems we are able to conduct infectious disease research and vaccine development previously not possible.
See our complete product pipeline below.
|TOTAL SALES OF
BRANDED REFERENCE DRUGS (2015)
PF582 Biologic Lucentis® marketed by Hoffmann-La Roche and Novartis AG
Global 2015 sales: $3.6 billion*
Used for the treatment of retinal diseases
Expected to initiate Phase 3 equivalence study in 2016
PF530 Biologic Betaseron® marketed by Bayer
Global 2015 sales: $0.9 billion*
Used to treat relapsing multiple sclerosis
Most advanced Betaseron biosimilar in development
Phase 1 trial initiated in March 2015
PF529 Biologic Neulasta marketed by Amgen
Global 2015 sales: $4.7 billion*
Used to reduce infections during chemotherapy
PF688 Biologic Cimzia® marketed by UCB
Global 2015 sales: $1.2 billion*
Used for the treatment of Crohn's disease and rheumatoid arthritis
PF708 Innovator drug Forteo® marketed by Eli Lilly
Global 2015 sales: $1.4 billion*
Used for the treatment of high fracture risk osteoporosis
Top-line data from bioequivalence study reported in 2Q16.
PF690 Biologic Oncaspar marketed by Sigma-Tau
Global 2015 sales: $121MM**
Used for the treatment of Acute Lymphoblastic Leukemia
PF444 Biologic Genotropin marketed by Pfizer
Global 2015 sales: $3.5 billion***
Used to treat certain growth disorders
PF694 Biologic Pegasys marketed by Hoffmann-La Roche
Global 2015 sales: $403 million**
Used for the treatment of chronic hepatitis C
*Based upon publicly available 2015 sales data for the branded pharmaceutical company.
**Approximate 2015 aggregate global branded sales of third-party greference drug per IMS data accessed May 4, 2016.
***Approximate 2015 aggregate global branded sales of third-party growth hormone products per IMS data accessed May 4, 2016.
Last Updated: 8/12/16
|PRE-CLINICAL||PHASE 1||PHASE 2|
FULLY FUNDED BY THE
*Development controlled by the US Government
Last Updated: 8/12/16